

Phillip R Pittman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8036993/publications.pdf>

Version: 2024-02-01

49
papers

1,950
citations

279798

23
h-index

254184

43
g-index

50
all docs

50
docs citations

50
times ranked

1480
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	19
2	Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine. <i>Vaccine</i> , 2021, 39, 2780-2790.	3.8	7
3	The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection. <i>Pathogens</i> , 2021, 10, 1646.	2.8	5
4	The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity. <i>Frontiers in Immunology</i> , 2020, 11, 555464.	4.8	2
5	Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile. <i>Vaccine: X</i> , 2020, 5, 100060.	2.1	3
6	Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. <i>New England Journal of Medicine</i> , 2019, 381, 1897-1908.	27.0	161
7	Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy. <i>Frontiers in Medicine</i> , 2019, 6, 229.	2.6	15
8	Rudolf Hess â€œ The Doppelg�nger conspiracy theory disproved. <i>Forensic Science International: Genetics</i> , 2019, 40, 18-22.	3.1	0
9	Biodefense and Special Pathogen Vaccines. , 2018, , 149-160.e7.		5
10	Human transcriptome response to immunization with live-attenuated Venezuelan equine encephalitis virus vaccine (TC-83): Analysis of whole blood. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 169-179.	3.3	6
11	Povidone Iodine Ointment Application to the Vaccination Site Does Not Alter Immunoglobulin G Antibody Response to Smallpox Vaccine. <i>Viral Immunology</i> , 2016, 29, 361-366.	1.3	2
12	Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans. <i>Vaccine</i> , 2016, 34, 424-429.	3.8	33
13	Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates. <i>Vaccine</i> , 2016, 34, 523-530.	3.8	39
14	Safety and immunogenicity of ricin vaccine, RVEc��, in a Phase 1 clinical trial. <i>Vaccine</i> , 2015, 33, 7299-7306.	3.8	26
15	Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response. <i>Vaccine</i> , 2015, 33, 2990-2996.	3.8	12
16	Human Antibody Responses to the Polyclonal Dryvax Vaccine for Smallpox Prevention Can Be Distinguished from Responses to the Monoclonal Replacement Vaccine ACAM2000. <i>Vaccine Journal</i> , 2014, 21, 877-885.	3.1	10
17	Transcriptional profiling of recall responses to Francisella live vaccine strain. <i>Pathogens and Disease</i> , 2014, 70, 141-152.	2.0	5
18	Anthrax vaccine adsorbed: Further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed. <i>Vaccine</i> , 2014, 32, 5131-5139.	3.8	8

#	ARTICLE	IF	CITATIONS
19	Effect of delayed anthrax vaccine dose on <i>Bacillus anthracis</i> protective antigen IgG response and lethal toxin neutralization activity. <i>Vaccine</i> , 2013, 31, 5009-5014.	3.8	5
20	Biodefense and special pathogen vaccines. , 2013, , 1008-1017.		1
21	Quantitative assessment of anthrax vaccine immunogenicity using the dried blood spot matrix. <i>Biologicals</i> , 2013, 41, 98-103.	1.4	4
22	Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83). <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1053-1065.	3.3	12
23	US Military contributions to the global response to pandemic chikungunya. <i>Vaccine</i> , 2012, 30, 6713-6720.	3.8	44
24	Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. <i>Vaccine</i> , 2011, 29, 3222-3229.	3.8	40
25	Th17 Cytokines in Recall Responses Against <i>Francisella Tularensis</i> in Humans. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 471-476.	1.2	21
26	Immune interference after sequential alphavirus vaccine vaccinations. <i>Vaccine</i> , 2009, 27, 4879-4882.	3.8	39
27	Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1528-1538.	1.6	20
28	Transcriptional profiling of <i>Francisella tularensis</i> infected peripheral blood mononuclear cells: a predictive tool for tularemia. <i>FEMS Immunology and Medical Microbiology</i> , 2008, 54, 92-103.	2.7	19
29	An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. <i>Vaccine</i> , 2008, 26, 4262-4266.	3.8	21
30	Biodefense and special pathogen vaccines. , 2008, , 1123-1133.		1
31	Transcriptome analysis of human immune responses following live vaccine strain (LVS) <i>Francisella tularensis</i> vaccination. <i>Molecular Immunology</i> , 2007, 44, 3173-3184.	2.2	28
32	Dominance of human innate immune responses in primary <i>Francisella tularensis</i> live vaccine strain vaccination. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1186-1188.	2.9	15
33	Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. <i>Vaccine</i> , 2006, 24, 3654-3660.	3.8	41
34	Immunization to Protect the US Armed Forces: Heritage, Current Practice, and Prospects. <i>Epidemiologic Reviews</i> , 2006, 28, 3-26.	3.5	93
35	An Assessment of Health Status among Medical Research Volunteers Who Served in the Project Whitecoat Program at Fort Detrick, Maryland. <i>Military Medicine</i> , 2005, 170, 183-187.	0.8	16
36	Protective Antigen and Toxin Neutralization Antibody Patterns in Anthrax Vaccinees Undergoing Serial Plasmapheresis. <i>Vaccine Journal</i> , 2005, 12, 713-721.	3.1	28

#	ARTICLE	IF	CITATIONS
37	Detection of antibodies to squalene. <i>Journal of Immunological Methods</i> , 2004, 286, 47-67.	1.4	36
38	Long-term health effects of repeated exposure to multiple vaccines. <i>Vaccine</i> , 2004, 23, 525-536.	3.8	23
39	Management Guidelines for Laboratory Exposures to Agents of Bioterrorism. <i>Journal of Occupational and Environmental Medicine</i> , 2004, 46, 791-800.	1.7	18
40	Analysis of Adverse Events after Anthrax Immunization in US Army Medical Personnel. <i>Journal of Occupational and Environmental Medicine</i> , 2003, 45, 222-233.	1.7	57
41	Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. <i>Vaccine</i> , 2002, 20, 1412-1420.	3.8	132
42	Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. <i>Vaccine</i> , 2002, 20, 2107-2115.	3.8	37
43	Aluminum-containing vaccine associated adverse events: role of route of administration and gender. <i>Vaccine</i> , 2002, 20, S48-S50.	3.8	73
44	Anthrax vaccine: short-term safety experience in humans. <i>Vaccine</i> , 2001, 20, 972-978.	3.8	103
45	Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. <i>Vaccine</i> , 2000, 19, 213-216.	3.8	50
46	Anthrax Vaccine. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 2104.	7.4	160
47	Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. <i>Vaccine</i> , 1999, 18, 181-189.	3.8	129
48	Immunologic Interference from Sequential Administration of Live Attenuated Alphavirus Vaccines. <i>Journal of Infectious Diseases</i> , 1998, 177, 634-641.	4.0	101
49	Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. <i>Vaccine</i> , 1996, 14, 337-343.	3.8	186